Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline [Seeking Alpha]
Sana Biotechnology, Inc. (SANA)
Company Research
Source: Seeking Alpha
Jul. 14, 2024 10:23 AM ET Sana Biotechnology, Inc. (SANA) Stock ALLO CRBU BioCGT Investor Follower s Follow Summary Sana Biotechnology is a biotech company focused on developing engineered allogeneic cells for diseases with unmet clinical needs. Sana's most advanced product candidates leverage CRISPR technology to modify cells, with positive pre-clinical trial results and first in-human trials starting in late 2023. The company's pipeline includes oncology, autoimmune disease, and regenerative medicine product candidates, with a focus on UP421 and SC291 for T1DM and B-cell malignancies, respectively. c Christoph Burgstedt Thesis Sana Biotechnology ( NASDAQ: SANA ) is a biotech company in the early clinical-stage, focused on the development of engineered allogeneic cells (genetically-modified cells from healthy donors) for the treatment of diseases with unmet clinical needs. Sana's most advanced product candidates, including UP421, SC291 and SC262, leverage
Show less
Read more
Impact Snapshot
Event Time:
SANA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SANA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SANA alerts
High impacting Sana Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
SANA
News
- Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day ConferenceGlobeNewswire
- TriArm Therapeutics Appoints Douglas E. Williams, Ph.D., as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Sana Biotechnology to Present at September 2024 Investor ConferencesGlobeNewswire
- Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific OfficerGlobeNewswire
- Sana Biotechnology, Inc. (NASDAQ: SANA) had its price target raised by analysts at Citigroup Inc. from $8.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
SANA
Earnings
- 8/8/24 - Miss
SANA
Sec Filings
- 10/15/24 - Form 3
- 10/9/24 - Form 4
- 10/8/24 - Form 8-K
- SANA's page on the SEC website